Spyre Therapeutics (SYRE) Equity Average: 2016-2025
Historic Equity Average for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $455.4 million.
- Spyre Therapeutics' Equity Average rose 29.80% to $455.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.4 million, marking a year-over-year increase of 29.80%. This contributed to the annual value of $350.9 million for FY2024, which is 199.51% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Equity Average is $455.4 million, which was down 2.93% from $469.2 million recorded in Q2 2025.
- Over the past 5 years, Spyre Therapeutics' Equity Average peaked at $500.2 million during Q1 2025, and registered a low of -$226.4 million during Q3 2023.
- In the last 3 years, Spyre Therapeutics' Equity Average had a median value of $263.3 million in 2024 and averaged $211.6 million.
- As far as peak fluctuations go, Spyre Therapeutics' Equity Average slumped by 398.44% in 2023, and later spiked by 1,476.85% in 2024.
- Over the past 5 years, Spyre Therapeutics' Equity Average (Quarterly) stood at $93.0 million in 2021, then plummeted by 36.64% to $58.9 million in 2022, then plummeted by 152.08% to -$30.7 million in 2023, then skyrocketed by 1,476.85% to $422.6 million in 2024, then climbed by 29.80% to $455.4 million in 2025.
- Its last three reported values are $455.4 million in Q3 2025, $469.2 million for Q2 2025, and $500.2 million during Q1 2025.